Uehara M, Sawai T
Department of Dermatology, Shiga University of Medical Science, Otsu, Japan.
Arch Dermatol. 1989 Mar;125(3):366-8.
Sensitization trials with dinitrochlorobenzene (DNCB) were performed in 150 patients with atopic dermatitis (AD) (24 severe, 86 moderate, and 40 mild cases). Dinitrochlorobenzene challenge tests were positive in 33% (8/24) of severe cases, in 95% (82/86) of moderate cases, and in 100% (40/40) of mild cases, indicating that DNCB contact sensitivity is diminished only in patients with AD who have extensive skin lesions. Of the 20 patients who were nonreactive on the first DNCB challenge tests, 18 became reactive on the second challenge tests that were performed at the time when the dermatitis was well controlled. It is likely that the suppressed contact sensitivity seen in patients with AD is secondary to the disease.
对150例特应性皮炎（AD）患者（24例重度、86例中度和40例轻度）进行了二硝基氯苯（DNCB）致敏试验。二硝基氯苯激发试验在33%（8/24）的重度病例、95%（82/86）的中度病例和100%（40/40）的轻度病例中呈阳性，表明只有在患有广泛皮肤病变的AD患者中，DNCB接触敏感性才会降低。在首次DNCB激发试验无反应的20例患者中，18例在皮炎得到良好控制时进行的第二次激发试验中出现反应。AD患者中所见的接触敏感性抑制很可能是该疾病的继发表现。
